Young Jin Dapagliflozin 10mg (Dapagliflozin Anhydrous Mixture)
Dapagliflozin Anhydrous Lactose Mixture 15.27mg
Tablet · Prescription medication
Young Jin Pharmaceutical Co., Ltd.
MFDS item code 202005356 · Approved 2020.07.23
This product's status changed to Approval withdrawn on 2024.12.23. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Improvement of glycemic control in type 2 diabetes mellitus
This medication is used to assist in controlling blood sugar for patients with type 2 diabetes. It can be administered alone or in combination with dietary and exercise therapies. It is particularly used in patients with cardiovascular diseases or risk factors among those whose blood sugar control is insufficient; for detailed clinical trial information, please refer to professional guidelines. Thus, it is effective in improving blood sugar management in patients with type 2 diabetes.
The recommended dose of this medicine is 10mg once daily for monotherapy and add-on combination therapy with other glucose-lowering agents, such as insulin. When this medicine is used in combination with insulin or an insulin secretagogue such as a sulfonylurea, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. For patients who have not previously received antidiabetic drug therapy, the recommended initial dose of this medicine when administered in combination with metformin is 5mg once daily or 10mg once daily. This medicine may be taken orally once daily at any time of the day, with or without food. The tablet should be swallowed whole. Treatment with this medicine should not be initiated in patients with an estimated glomerular filtration rate [estimated glomerular filtration rate (eGFR)] below 60 mL/min/1.73 m2. This medicine should be discontinued if the glomerular filtration rate remains below 45 mL/min/1.73 m2. No dose adjustment is necessary in patients with mild renal impairment. No dose adjustment is necessary in patients with mild or moderate hepatic impairment. For patients with severe hepatic impairment, an initial dose of 5 mg is recommended. If well tolerated, this dose may be increased to 10mg. Elderly patients (≥ 65 years): In general, dose adjustment based on age is not recommended. Renal function and the risk of volume depletion should be considered. As treatment experience in patients over 75 years of age is limited, initiation of treatment with this medicine is not recommended.
This medication should not be used by patients who are allergic to the main ingredient or additives. It should also not be administered to patients with type 1 diabetes or diabetic ketoacidosis. This medication contains anhydrous lactose and should not be used in patients with lactose intolerance or specific genetic metabolic disorders. Patients with severely impaired kidney function, end-stage renal disease, or those on dialysis should not be given this medication. Due to the risk of acute kidney injury, it should be used with caution in patients with reduced kidney function or blood volume, and can be temporarily discontinued if necessary. It is not recommended for use in patients with severe heart failure. This medication contains specific colorants, and patients allergic to them should take caution. Symptoms of hypoglycemia may occur; when used with insulin or sulfonylureas that induce hypoglycemia, careful monitoring of blood sugar is required. Fluid loss or hypotension may occur, so elderly patients or those on diuretics should have their condition checked periodically. During the use of this medication, there may be an increased risk of genital infections and urinary tract infections; if signs of infection occur, immediate consultation with healthcare providers is necessary. Women who are pregnant or breastfeeding should not use this medication, and treatment should be discontinued if pregnancy is confirmed. There is no specific antidote in case of overdose; symptomatic treatment should be administered according to symptoms. This medication does not greatly affect driving or machinery operation, but care should be taken if there is a risk of hypoglycemia.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to avoid exposure to air or moisture. Additionally, it is best to store the medication at room temperature between 1°C and 30°C. Avoid extreme heat or cold.
Yellow, biconvex, diamond-shaped film-coated tablet
28 tablets/box [7 tablets/PTP X 4]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Dapagliflozin Anhydrous Lactose Mixture 15.27mg
Tablet · Prescription medication
Young Jin Pharmaceutical Co., Ltd.
Dapagliflozin Anhydrous Lactose Mixture 7.635mg
Tablet · Prescription medication
International Pharmaceuticals Co., Ltd.

Dapagliflozin Anhydrous Lactose Mixture 15.27mg
Tablet · Prescription medication
International Pharmaceutical Co., Ltd.
Dapagliflozin Anhydrous Lactose Mixture 7.635mg
Tablet · Prescription medication
Shinil Pharmaceutical Co., Ltd.

Dapagliflozin Anhydrous Lactose Mixture 15.27mg
Tablet · Prescription medication
Sinil Pharmaceutical Co., Ltd.
Dapagliflozin Anhydrous Lactose Mixture 7.635mg
Tablet · Prescription medication
Dongwha Pharmaceutical Co., Ltd.

Dapagliflozin Anhydrous Lactose Mixture 15.27mg
Tablet · Prescription medication
Donghwa Pharmaceutical Co., Ltd.
Dapagliflozin Anhydrous Lactose Mixture 7.635mg
Tablet · Prescription medication
Albozen Korea Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.